Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare treatment of outpatient reimbursement for laboratory tests.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Duration: July 1, 2014
to
August 31, 2018
General Issues: Medicare/Medicaid , Medical/Disease Research/Clinical Labs
Spending: about $680,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: House of Representatives, U.S. Senate, Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Daniel Todd
Senior Health Counsel, Senate Finance Committee
Special Assistant, Office of Admin Ctr-Medicare & Medicaid
Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
Paul Edattel
Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2018
Todd Strategy, LLC terminated an engagement in which they represented Myriad Genetic Laboratories, Inc. on Nov. 5, 2018.
Original Filing: 301000032.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare treatment of outpatient reimbursement for laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2018
Todd Strategy, LLC filed a lobbying registration on Nov. 1, 2018 to represent Myriad Genetic Laboratories, Inc. (Formerly Known as Myriad Genetics, Inc.), effective Sept. 1, 2018.
Original Filing: 300999890.xml
Issue(s) they said they’d lobby about: Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare treatment of outpatient reimbursement for laboratory tests.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced). .
3rd Quarter, 2018
Todd Strategy, LLC terminated an engagement in which they represented Myriad Genetic Laboratories, Inc. on Nov. 1, 2018.
Original Filing: 300999896.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare treatment of outpatient reimbursement for laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2018
Todd Strategy, LLC filed a lobbying registration on Oct. 22, 2018 to represent Myriad Genetics, Inc. (Formerly Known as Myriad Genetic Laboratories, Inc.), effective Sept. 1, 2018.
Original Filing: 300994857.xml
Issue(s) they said they’d lobby about: Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare treatment of outpatient reimbursement for laboratory tests.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced). .
3rd Quarter, 2018
In Q3, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990268.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare treatment of outpatient reimbursement for laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2018
In Q2, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on July 19, 2018.
Original Filing: 300972023.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare treatment of outpatient reimbursement for laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2018
In Q1, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on April 20, 2018.
Original Filing: 300956259.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare treatment of outpatient reimbursement for laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2017
In Q4, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934343.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2017
In Q3, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915860.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2017
In Q2, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on July 20, 2017.
Original Filing: 300896484.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2017
In Q1, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on April 20, 2017.
Original Filing: 300871946.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2016
In Q4, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on Jan. 24, 2017.
Original Filing: 300858899.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2016
In Q3, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on Oct. 18, 2016.
Original Filing: 300829993.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2016
In Q2, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on July 20, 2016.
Original Filing: 300816932.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2016
In Q1, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on April 20, 2016.
Original Filing: 300803470.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Medicare Treatment of Outpatient Reimbursement for Laboratory tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2015
In Q4, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on Jan. 20, 2016.
Original Filing: 300784098.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2015
In Q3, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on Oct. 20, 2015.
Original Filing: 300764951.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2015
In Q2, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on July 20, 2015.
Original Filing: 300745372.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2015
In Q1, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on April 20, 2015.
Original Filing: 300724519.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of laboratory developed tests.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2014
In Q4, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on Jan. 20, 2015.
Original Filing: 300707965.xml
Lobbying Issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014.
Implementation of changes to Medicare payment for clinical laboratory tests.
FDA regulation of Laboratory Developed Tests.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2014
In Q3, Todd Strategy, LLC lobbied for Myriad Genetic Laboratories, Inc. , earning $40,000. The report was filed on Oct. 20, 2014.
Original Filing: 300685324.xml
Lobbying Issues
PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2014
Todd Strategy, LLC filed a lobbying registration on Aug. 13, 2014 to represent Myriad Genetic Laboratories, Inc., effective July 1, 2014.
Original Filing: 300672039.xml
Issue(s) they said they’d lobby about: Implementation of PL 113-93: Protecting Access to Medicare Act of 2014.
Medicare payment for clinical laboratory tests.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics.
Legislation to further regulate clinical labs under CLIA and/or FDA (legislation not yet introduced). .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate